Jane Rhodes, Verge Genomics Chief Business Officer
Verge Genomics teams up with AstraZeneca in drug discovery deal
Verge Genomics has secured its largest deal yet, linking up with AstraZeneca’s rare disease division Alexion in a deal worth up to $882 million. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
